標題: Serial serologic changes of hepatitis D virus in chronic hepatitis B patients receiving nucleos(t)ides analogues therapy
作者: Jang, Tyng-Yuan
Wei, Yu-Ju
Hsu, Cheng-Ting
Hsu, Po-Yao
Liu, Ta-Wei
Lin, Yi-Hung
Liang, Po-Cheng
Hsieh, Meng-Hsuan
Ko, Yu-Min
Tsai, Yi-Shan
Chen, Kuan-Yu
Lin, Ching-Chih
Tsai, Pei-Chien
Wang, Shu-Chi
Huang, Ching-, I
Yeh, Ming-Lun
Lin, Zu-Yau
Chen, Shinn-Cherng
Chuang, Wan-Long
Huang, Jee-Fu
Dai, Chia-Yen
Huang, Chung-Feng
Yu, Ming-Lung
交大名義發表
生物科技學系
National Chiao Tung University
Department of Biological Science and Technology
關鍵字: hepatitis D;nucleos(t)ides analogues;prevalence;spontaneous clearance
公開日期: 1-一月-1970
摘要: Background and Aim The serial serologic changes of hepatitis D virus (HDV) infection among chronic hepatitis B virus (HBV) infected patients who received oral nucleotide/nucleoside analogues are elusive. Methods Serum anti-HDV and HDV RNA among chronic hepatitis B (CHB) patients were tested at the time of initiating anti-HBV therapy and subsequently during the follow-up period. Results The seropositive rate of anti-HDV and HDV RNA among 2850 CHB patients, was 2.7% and 0.9%, respectively. Factors associated with anti-HDV seropositivity were platelet counts (odds ratio [OR]/95% confidence intervals [CI]: 0.995/0.992-0.999; P = 0.006), HBV DNA levels (OR/CI: 0.81/0.70-0.94; P = 0.005), and hepatitis B e-antigen (HBeAg) seropositivity (OR/CI: 0.22/0.05-0.95; P = 0.04). The only factor associated with HDV RNA positivity among anti-HDV seropositive patients was age (OR/CI: 0.95/0.90-1.00; P = 0.03). The spontaneous clearance rate of serum anti-HDV antibody was 3.0 per 100 person-years with a median follow-up period of 3.5 years (range 2-12 years), whereas the seroclearance rate of HDV RNA was 4.3 per 100 person-years among anti-HDV seropositive patients after a median follow-up period of 6.0 years (range 2-11 years). A baseline anti-HDV titer < 0.5 cut-off index was the only factor predictive of anti-HDV seroclearance (hazard ratio [HR]/CI: 30.11/3.73-242.85; P = 0.001). Conclusions HDV infection was not common among patients treated for HBV in Taiwan. Seroclearance of anti-HDV and HDV RNA did occur over time, albeit the chance is rare.
URI: http://dx.doi.org/10.1111/jgh.15061
http://hdl.handle.net/11536/154154
ISSN: 0815-9319
DOI: 10.1111/jgh.15061
期刊: JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
起始頁: 0
結束頁: 0
顯示於類別:期刊論文